ANTICANCER COMBINATION THERAPY WITH CD73 ANTAGONIST ANTIBODY AND PD-1/PD-L1 AXIS ANTAGONIST ANTIBODY

Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of a CD73 antagonistic antibody alone or in combination with a PD-1/PD-L1 axis antagonist antibody. L'invention concerne des méthodes de traitement du cancer,...

Full description

Saved in:
Bibliographic Details
Main Authors POSTELNEK, Jennifer R, ALTURA, Rachel A, PEREZ, Raymond P, KLIPPEL-GIESE, Anke, HILT, Edward, ZHAO, Yue, SANGHAVI, Kinjal
Format Patent
LanguageEnglish
French
Published 17.10.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
TESTING
Online AccessGet full text

Cover

More Information
Summary:Provided herein are methods for treating cancer, comprising administering to a subject having cancer a therapeutically effective amount of a CD73 antagonistic antibody alone or in combination with a PD-1/PD-L1 axis antagonist antibody. L'invention concerne des méthodes de traitement du cancer, comprenant l'administration à un sujet atteint d'un cancer d'une quantité thérapeutiquement efficace d'un anticorps antagoniste de CD73 seul ou combiné à un anticorps antagoniste de l'axe PD-1/PD-L1.
Bibliography:Application Number: WO2019US27219